Clear corneal phaco reduces IOP

Article

Clear corneal phacoemulsification induces a small reduction in intraocular pressure (IOP), according to the results of a study published in the December 2006 issue of the Journal of Glaucoma.

Clear corneal phacoemulsification induces a small reduction in intraocular pressure (IOP), according to the results of a study published in the December 2006 issue of the Journal of Glaucoma.

Bradford Shingleton, MD and co-workers at Ophthalmic Consultants of Boston, USA, conducted a retrospective study of the long-term changes in IOP after clear corneal phacoemulsification. They examined 55 eyes of 48 patients with open-angle glaucoma, 44 eyes of 41 patients with suspected glaucoma and a control group of 59 eyes of 59 patients with no glaucoma. All patients completed a follow-up period of at least three years.

At three years follow-up, a mean IOP decrease of 1.4 mmHg was recorded among patients with glaucoma and glaucoma suspects. In the control group, there was a mean decrease of 1.7 mmHg. Most patients achieved IOPs equal or lower to their preoperative IOP without increasing the number of medications used.

At final follow-up, IOP remained significantly lower in all three groups. At a mean of five years, IOP had decreased by an average of 1.8 mmHg for glaucoma patients, 1.3 mmHg for glaucoma suspects and by 1.5 mmHg in the control group. Additionally, 76% of glaucoma patients, 79% of glaucoma suspects and 83% of the control group maintained IOPs of less or equal to the baseline without increasing the number of glaucoma medications.

The authors concluded that clear corneal phacoemulsification can induce a small but significant reduction in IOP that is sustained up to five years postoperatively.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.